Clinical Trials Logo

Diffuse Midline Glioma clinical trials

View clinical trials related to Diffuse Midline Glioma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04264143 Completed - Clinical trials for Diffuse Intrinsic Pontine Glioma

CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas

Start date: March 10, 2020
Phase: Phase 1
Study type: Interventional

The blood brain barrier (BBB) prevents some drugs from successfully reaching the target source. Convection-Enhanced Delivery (CED) is a method of direct infusion of drugs under controlled pressure to the tumor that may reduce systemic side effects of drugs in the patient. The purpose of this Phase I study is to find the maximum tolerated dose of MTX110 (a water-soluble Panobinostat nanoparticle formulation) and Gadolinium that can be given safely in children with newly diagnosed diffuse midline gliomas. All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor over 9-11 days.